Synovial macrophage and fibroblast-like synoviocyte (SM/FLS)

Synovial macrophages and fibroblast-like synoviocytes (FLS) are the primary cellular components of the synovial lining in diarthrodial joints. Synovial macrophages, or Type A synoviocytes, are immune cells that maintain joint homeostasis through phagocytosis and the secretion of regulatory cytokines (Nature Reviews Rheumatology, 2020). Fibroblast-like synoviocytes, or Type B synoviocytes, are specialized mesenchymal cells responsible for producing the extracellular matrix and synovial fluid components like hyaluronan (Arthritis & Rheumatology, 2019). In inflammatory arthropathies such as rheumatoid arthritis, these cells become pathologically activated, leading to synovial hyperplasia and the formation of an invasive 'pannus' (PubMed, 2021). Activated synovial macrophages produce high levels of pro-inflammatory cytokines, including TNF-alpha, IL-1, and IL-6, which drive the chronic inflammatory state (StatPearls, 2023). Simultaneously, FLS secrete matrix metalloproteinases (MMPs) and RANKL, which directly mediate the destruction of cartilage and bone (NIH, 2022). Current pharmacological treatments, such as TNF inhibitors and JAK inhibitors, work by neutralizing the products of these cells or blocking their internal signaling cascades (PubChem, 2023). Because this entry describes a heterogeneous cell population rather than a single protein or nucleic acid, it is classified as a cellular target rather than a molecular one.

Other names

Type A synoviocyteType B synoviocyteSynovial lining cellIntimal macrophageSynovial fibroblastFibroblast-like synoviocyteFLS

Drugs target these cells by inhibiting the production or activity of pro-inflammatory cytokines (e.g., TNF, IL-6) and blocking intracellular signaling pathways (e.g., JAK/STAT) to reduce synovial inflammation and joint destruction.